Pharmacokinetic Study of Aerosolized Colimycin in Cystic Fibrosis
NCT ID: NCT01537614
Last Updated: 2016-10-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
7 participants
INTERVENTIONAL
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.
NCT03312075
Pharmacokinetics of Polymyxin B in Adult Patients With Cystic Fibrosis
NCT04335370
Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
NCT05561764
A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
NCT03000348
The Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis
NCT00405665
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COLIMYCINE injectable
COLIMYCINE injectable
2 MILLIONS UI
COLIMYCINE inhalation
COLIMYCINE inhalation
2 MILLION UI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COLIMYCINE inhalation
2 MILLION UI
COLIMYCINE injectable
2 MILLIONS UI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suffering from stable cystic fibrosis
* Colonized by P. aeruginosa
* Having given informed consent.
* Able to follow the protocol
* Having a social insurance
Exclusion Criteria
* Allergy to colistin or polymixins
* Myasthenia
* Recent severe hemoptysis
* Liver cirrhosis and hepatic insufficiency
* Hypoalbuminemia
* Colonization by Burkholderia cepaea or Stenotrophomonas maltophilin
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Poitiers University Hospital
Poitiers, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COLI-VLM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.